BPH Clinical Trial
Official title:
Loop Diuretics During Morcellation to Improve Same-day Discharge Rates After Holmium Laser Enucleation of the Prostate (HoLEP)
Holmium Laser Enucleation of the Prostate (HoLEP) is a size-independent treatment option for benign prostatic hypertrophy (BPH) as recommended by the American Urological Association (AUA) Guidelines. Loop diuretics (furosemide) have been given historically during the morcellation portion of HoLEP to promote urine production in the post-operative setting and to minimize the impact of fluid absorption during long periods of morcellation. The intra-operative use of 20mg IV furosemide in perioperative HoLEP pathways has been propagated with the dissemination of HoLEP across North America without evidence to support its routine administration. With increasing surgical efficiency from improvements in laser and morcellator technology, the role of intra-operative furosemide is unknown. This study is designed to assess if there is a significant difference in same day discharge rates after Holmium Laser Enucleation of the Prostate (HoLEP) with and without IV furosemide. .
Holmium Laser Enucleation of the Prostate (HoLEP) is a size-independent treatment option for benign prostatic hypertrophy (BPH) as recommended by the American Urological Association (AUA) Guidelines. Loop diuretics (furosemide) have been given historically during the morcellation portion of HoLEP to promote urine production in the post-operative setting and to minimize the impact of fluid absorption during long periods of morcellation. The intra-operative use of 20mg IV furosemide in perioperative HoLEP pathways has been propagated with the dissemination of HoLEP across North America without evidence to support its routine administration. This single-center randomized controlled trial is designed to assess if there is a significant difference in same day discharge rates after Holmium Laser Enucleation of the Prostate (HoLEP). We currently attempt to perform HoLEP as a same-day discharge (SDD) procedure, however one of the main limiting factors in SDD is hematuria. Loop diuretics (furosemide) have been administered at the time of morcellation as a part of our HoLEP pathway to increase post-operative urinary output and reduce clinically significant gross hematuria and clot-formation. The objective of our study will be to assess if SDD rates are non-inferior in those patients who do not receive furosemide diuretics versus those that do. Patients will be randomized 1:1 to 20mg of IV lasix versus control. Patients and the surgeon/post-operative care team (fellow, residents, and nursing team) will be blinded to the treatment allocation. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02974751 -
Global Post-Market Registry Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue
|
||
Terminated |
NCT04398966 -
Prostatic Artery Embolization vs Medication for Benign Prostatic Hyperplasia
|
N/A | |
Completed |
NCT04029012 -
Penthrox in Rezūm BPH
|
Phase 4 | |
Recruiting |
NCT03912558 -
Pilot Study to Assess the Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in BPH Patients.
|
N/A | |
Completed |
NCT00527488 -
Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia.
|
Phase 2 | |
Recruiting |
NCT06323109 -
US Imaging for the Assessment of LUTS
|
||
Completed |
NCT05628025 -
Simulation-Based Enucleation Training: Initial Experience Using 3D-printed Organ Phantoms
|
||
Completed |
NCT00407329 -
Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia
|
N/A | |
Completed |
NCT00256399 -
Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)
|
N/A | |
Terminated |
NCT03994263 -
A Prospective Study to Observe the Mechanism of Action of the MediTate iTind in Subjects With Symptomatic BPH With MRI
|
N/A | |
Completed |
NCT03772808 -
Effects of LycoComfort™ Supplementation on Symptoms Associated With Lower Urinary Tract Symptoms (LUTS)
|
N/A | |
Completed |
NCT05818670 -
Comparison Between Tamsulosin and Tadalafil in Management of Benign Prostatic Hyperplasia Long Term Study
|
Phase 4 | |
Withdrawn |
NCT02961114 -
Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04198103 -
Transperineal Laser Ablation for Percutaneous Treatment of Benign Prostatic Hyperplasia
|
N/A | |
Completed |
NCT00696761 -
The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients
|
Phase 4 | |
Completed |
NCT00199550 -
Bipolar vs Monopolar Transurethral Resection of the Prostate (TURP)
|
Phase 4 | |
Completed |
NCT02702947 -
Efficacy of Prunus Domestica Extract in BPH
|
Phase 4 | |
Completed |
NCT00154843 -
A Clinical Study to Determine Factors Affecting Absorption and Serum Levels of Lycopene After Supplementation
|
Phase 2 | |
Completed |
NCT00037141 -
Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05719220 -
Effect of Group Preoperative Pelvic Floor Training for HoLEP
|